Trial · NCT07026968
A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes
NCT07026968, Phase 3, Active not recruiting, CSPC Ouyi Pharmaceutical Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes. Trials, record NCT07026968. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07026968
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes
- NCT number
- NCT07026968
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 815 participants, estimated
- Lead sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Conditions
- Type 2 Diabetes
- Interventions
Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR, Prusogliptin placebo, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR, Prusogliptin, Dapagliflozin(high dose) placebo, Dapagliflozin (low dose), plus metformin XR, Prusogliptin placebo, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose), plus metformin XR, Prusogliptin, Dapagliflozin (high dose) placebo, Dapagliflozin(low dose) placebo, plus metformin XR
- First posted
- 2025-06-18
- Last updated
- 2026-04-06
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean change from baseline in HbA1c at Week 24 | From baseline to week 24 | |
| Secondary | Proportion of participants with HbA1c of ≤6.5% and HbA1c of ≤7% at week 24 | From baseline to week 24 | |
| Secondary | Relative change from baseline in HbA1c at week 12 | From baseline to week 12 | |
| Secondary | Relative change from baseline in FPG at week 12 and week 24 | From baseline to week 12 and week 24 | |
| Secondary | Relative change from baseline in 2h-PPG at week 12 and week 24 | From baseline to week 12 and week 24 | |
| Secondary | Relative change from baseline in weight at week 12 and week 24 | From baseline to week 12 and week 24 | |
| Secondary | Relative change from baseline in blood pressure at week 12 and week 24 | From baseline to week 12 and week 24 | |
| Secondary | Relative change from baseline in blood lipid level at week 12 and week 24 | From baseline to week 12 and week 24 | |
| Secondary | Relative change from baseline in 7-point blood glucose levels and average post-meal blood glucose increments at week 24 | From baseline to week 24 | |
| Secondary | Proportion of participants who received rescue treatment after 24 weeks of treatment | From baseline to week 24 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07026968
GET https://conductscience.org/api/trials/v1/NCT07026968/registered